News und Analysen
The Non-Financial Rating Agency Vigeo-Eiris Classifies Korian 1st Company in the Healthcare Sector for its ESG1 Commitments
Korian (Paris:KORI), the leading European care services company for elderly and fragile people, welcomes the report published early October by the non-financial rating agency Vigeo-Eiris (V.E), a
Humana Expands Footprint, Health Plan Choices in New Jersey
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding health plan choices for Medicare beneficiaries in New Jersey by once again adding counties in which its 2022 Humana
Humana Healthy Horizons in Kentucky Announces $207,000 Investment to Reduce “Digital Divide” and Improve Access to Health Care in Lyon County, KY
Humana Healthy Horizons in Kentucky, Humana’s (NYSE: HUM) Kentucky Medicaid Plan, is pleased to announce a $207,000 investment that will upgrade infrastructure in Lyon County, KY in order to
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides
Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces today that it will give an oral
For First Time, Humana Offering Medicare Advantage Plans in Connecticut
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding health plan choices for Medicare beneficiaries in Connecticut by offering affordable Humana Medicare Advantage plans in
Ipsen erweitert seine präklinische Forschungs- und Entwicklungspipeline für Onkologie im Rahmen einer exklusiven weltweiten Zusammenarbeit mit Accent Therapeutics um ein weiteres Programm mit Fokus auf das RNA-modifizierende Protein METTL3
Haftungsausschluss: Nur für internationale Medien und Investoren bestimmt
Ipsen (Euronext: IPN; ADR: IPSEY) und Accent Therapeutics (Accent) haben eine exklusive weltweite
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
Regulatory News:
Disclaimer: Intended for international media and investor audiences only
Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and
Lucid Diagnostics Announces Pricing of Initial Public Offering
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of
Simulations Plus Announces Cash Dividend
Simulations Plus, Inc. (Nasdaq: SLP) announced today that the Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock, payable on November 1
Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK
DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an awareness and education
Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK
DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an awareness and education
Humana Continues Extensive Statewide Expansion in Tennessee
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced another major expansion of its Medicare Advantage (MA) offerings across Tennessee for the 2022 plan year. It’s part of
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2021, ended August 31, 2021, after the close of the
Acadia Healthcare Names Osei Mevs as Vice President of Government Relations
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that J.L. Osei Mevs has been named Vice President of Government Relations. In this role, Mevs will oversee the Company’s government
Acadia Healthcare Names David Keys as Chief Development Officer
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that David M. Keys, CFA, has been named Chief Development Officer. Keys will focus on mergers & acquisitions, de novo development and
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies
Acadia Healthcare Announces Date for Third Quarter 2021 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2021 results on Thursday, October 28, 2021, after the close of the market. Acadia will conduct
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris
Compartment: B
ISIN code: FR0011341205
Website: www.nanobiotix.com
Date
Number of Shares
Outstanding
Savara to Present at the Inaugural Piper Sandler Lung Day
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the